Of note, a pilot study on an animal model, concerning IL-17A involved both in the pathogenesis of psoriasis and HT inflammatory model signaling, indicated IL-17 antibodies as a potential treatment target for HT and associated end-organ dysfunction [40]. This evidence concerns the gene IL17A and psoriasis.